載入...
Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it...
Na minha lista:
| 發表在: | Ann Neurol |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6771589/ https://ncbi.nlm.nih.gov/pubmed/31168802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25513 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|